202 related articles for article (PubMed ID: 23883350)
1. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation.
O'Brien TJ; Kalmin MM; Harralson AF; Clark AM; Gindoff I; Simmens SJ; Frankfurter D; Gindoff P
Reprod Biol Endocrinol; 2013 Jul; 11():71. PubMed ID: 23883350
[TBL] [Abstract][Full Text] [Related]
2. Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome.
O'Brien TJ; Harralson AF; Tran T; Gindoff I; Orkunoglu-Suer FE; Frankfurter D; Gindoff P
Reprod Biol Endocrinol; 2014 May; 12():36. PubMed ID: 24886133
[TBL] [Abstract][Full Text] [Related]
3. Association between LH receptor regulation and ovarian hyperstimulation syndrome in a rodent model.
Zheng C; Gulappa T; Menon B; Menon KMJ
Reproduction; 2020 Aug; 160(2):239-245. PubMed ID: 32422603
[TBL] [Abstract][Full Text] [Related]
4. The polymorphic insertion of the luteinizing hormone receptor "insLQ" show a negative association to LHR gene expression and to the follicular fluid hormonal profile in human small antral follicles.
Borgbo T; Chrudimska J; Macek M; Jeppesen JV; Bøtkjær JA; Kristensen SG; Macklon KT; Ernst E; Hansen LL; Yding Andersen C
Mol Cell Endocrinol; 2018 Jan; 460():57-62. PubMed ID: 28684292
[TBL] [Abstract][Full Text] [Related]
5. The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation.
Huang X; Li L; Hong L; Zhou W; Shi H; Zhang H; Zhang Z; Sun X; Du J
Clin Endocrinol (Oxf); 2015 Apr; 82(4):577-83. PubMed ID: 25132286
[TBL] [Abstract][Full Text] [Related]
6. The implication of single-nucleotide polymorphisms in ovarian hyperstimulation syndrome.
Ghaderian SMH; Akbarzadeh R; Mohajerani F; Khodaii Z; Salehpour S
Mol Reprod Dev; 2019 Aug; 86(8):964-971. PubMed ID: 31115963
[TBL] [Abstract][Full Text] [Related]
7. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
8. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
9. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
Orvieto R
J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
[TBL] [Abstract][Full Text] [Related]
10. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
11. Symposium: Update on prediction and management of OHSS. Genetics of ovarian hyperstimulation syndrome.
Rizk B
Reprod Biomed Online; 2009 Jul; 19(1):14-27. PubMed ID: 19573286
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
[TBL] [Abstract][Full Text] [Related]
13. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
14. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
15. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
16. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
18. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
19. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
Lee KL; Couchman GM; Walmer DK
J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
[TBL] [Abstract][Full Text] [Related]
20. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
